AAX Biotech secures investment from Trio Impact Invest
Daniel X Johansson, CEO and CSO of AAX Biotech (left), and Siimon Vaske, CEO of Trio Impact Invest AB (right).
Biotech company AAX Biotech, a leading innovator in technologies for antibody-based medicines, today announced that Trio Impact Invest AB has invested in AAX Biotech. The investment supports the continued development and scaling of the company’s antibody technology platforms, enabling expanded application areas and strengthened industry collaborations.
AAX Biotech develops proprietary technologies, including Seqitope® and Opti-mAb®, designed to advance antibody discovery, optimization and developability across modern therapeutic formats. Through these platforms, the company collaborates with partners across antibody discovery and engineering, delivering advanced solutions that enhance antibody performance and support clinical success.
The investment follows a period of technological and commercial progress at AAX Biotech, including the implementation of advanced automation to enhance platform scalability and several new collaborations, among them one with global pharmaceutical company Daiichi Sankyo.
Trio Impact Invest’s investment will be allocated to platform advancement and continued development of industry partnerships.
“This investment marks the next phase of platform development and expansion,” said Daniel X Johansson, CEO and CSO of AAX Biotech. “With Trio Impact Invest’s support, we can scale our proprietary platforms, broaden their impact across antibody discovery and development, and strengthen collaborations with new and existing partners.”
Trio Impact Invest is a Swedish deep tech venture capital firm investing in early-stage, research-intensive companies with the potential for significant societal and commercial impact. Trio Impact Invest focuses on enabling technologies and long-term value creation through active ownership and close collaboration with founders.
“We’re thrilled to make our first investment from Trio Impact Invest in AAX Biotech, backing a team whose enabling technology can meaningfully improve how antibody-based medicines are discovered and optimized,” said Siimon Vaske, CEO of Trio Impact Invest AB. “AAX combines strong scientific capability with a clear roadmap to scale its proprietary platform and drive impact through collaborations and continued technology development.”
For more information, please contact:
Daniel X Johansson, CEO and CSO
daniel.johansson@aaxbiotech.com
+46 704902433
About AAX Biotech AB
AAX Biotech AB is a biotech company specializing in next-generation antibody therapeutics. The company offers two unique and proprietary technologies, Seqitope® and Opti-mAb®, that enable high-throughput and high-resolution epitope mapping as well as stabilization of single chain variable fragments (scFv) for applications such as bispecific antibodies and CAR-T cells. Both technologies aim to produce better and more effective antibody-based medicines. These innovations position AAX Biotech as a key player in the rapidly growing antibody therapeutics market. AAX Biotech is founded by experts from Karolinska Institutet in Stockholm, Sweden. Visit aaxbiotech.com to learn more and follow AAX Biotech on LinkedIn.
About Trio Impact Invest AB
Trio Impact Invest is a Swedish deep tech venture capital firm investing in research-intensive, early-stage companies with the potential to create significant societal and commercial impact. Trio backs enabling technologies across the deep tech landscape—spanning fields such as life science, advanced materials, energy and climate, industrial and manufacturing tech, digitalization and AI, and security and resilience—and supports long-term value creation through active ownership and close partnership with founders.
